Autres langues Inventiva

Actions

IVA

FR0013233012

Marché Fermé - Euronext Paris Autres places de cotation 17:29:00 10/06/2024			Après clotûre 19:50:38
3,23 ^EUR	+1,89 %		3,22	-0,31 %

24/05	Inventiva : UBS Group solde sa participation	CF
22/05	Correctif: Inventiva: visibilité jusqu'au 3e trimestre 2024	AO

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Inventiva : 14. Brochure General Assembly 06 20 2024	30/05
Inventiva : 7. Special Report of the Board of Directors on Bonus Share Issues – AGA 2023 – 25 03 2024	30/05
Inventiva : 1. Agenda of Ordinary and Extraordinary General Meeting – 06 20 2024	30/05
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents	30/05
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents	30/05
Inventiva : Franchissement de seuil	27/05
Inventiva : UBS Group solde sa participation	24/05
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024	22/05
Inventiva : le titre recule, la trésorerie inquiète	22/05
Borsa di Italia: stasera si pubblica	22/05
Bolsa de Madrid: Ya-sabes-quién publica esta noche	22/05
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update	21/05
Inventiva : le DMC recommande la poursuite d'une étude	17/05
Inventiva, Inc. Announces Amendments to the Pipeline Programs and Clinical Trials	16/05
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH	16/05
Inventiva : Notice of meeting to the Ordinary and Extraordinary General Meeting dated June 20, 2024 - Form 6-K	13/05
Borsa : Milano allunga con Stellantis e chiude ai massimi dal 2008 (+0,4%) -3-	13/05
Inventiva : résultats complémentaires de phase 2 dans la NASH	13/05
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor	13/05
Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor	13/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Inventiva

Actions

IVA

FR0013233012

Autres langues

Filtres